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ABSTRACT
Relapsed acute myeloid leukemia (AML) in adults has a poor prognosis if treated with chemotherapy alone. Case
series have previously supported the role of myeloablation and autologous transplantation as a potentially curative
treatment. This study aimed to use the large numbers and extended follow-up data in the British Society of Blood
and Marrow Transplantation (BSBMT) registry database to establish long-term outcomes and relate these to
biological and procedural factors. The BSBMT registry database was used to retrospectively identify 152 adult
patients (age, 16–69 years) with AML in second remission treated with autologous transplantation in 1982–2003.
Cytogenetic data were available for 68% of the patients; of these, at diagnosis, 42% had good risk features, 57% had
standard risk features, and 1% had poor risk features. Conditioning regimens varied; autologous rescue was
provided with bone marrow (BM) (71%), peripheral blood stem cells (PBSCs) (18%), or both (11%), which were
harvested during first complete remission (CR1) and/or second CR (CR2). Median follow-up was 84 months (range,
2–200 months). At 10 years, actuarial overall survival (OS) was 32%, progression-free survival (PFS) was 28%, and
relapse rate (RR) was 57%. The 100-day nonrelapse mortality (NRM) was 7%, rising to 11% at 1 year and to 14%
at 10 years. OS was significantly related to M3 subtype (5-year OS, 66%; P  .005), patient age at diagnosis (P 
.005) and transplantation (P  .026), and length of CR1, with greatest significance if the patient was dichotomized
at CR1 duration of < 8 months or > 8 months (P  .0001). There was no difference in OS between regimens
containing total body irradiation (TBI) and chemotherapy alone (P  .7). In relation to the nature of autologous
graft material, there was improved OS (P .025) and PFS (P .009) with the use of cells harvested entirely in CR1
compared with cells harvested in CR2 or in both CR1 and CR2. Engraftment times were significantly shortened
with the use of PBSCs alone or in combination with BM compared with BM alone (P  .0001), but there was no
significant long-term impact on OS, PFS, RR, or NRM. This study provides long-term follow-up data in one of the
largest series of patients with standard-risk and good-risk AML in CR2 treated with autologous transplantation and
supports earlier observations that long-term survival is achievable in about 1/3 of patients overall and in about 2/3
of patients with M3 with a relatively low NRM. Outcomes are better in patients with CR1 > 8 months by use of
grafts obtained entirely in CR1 and use of PBSCs. TBI conditioning did not confer an advantage. Randomized
studies against unrelated donor transplantation are warranted.
© 2006 American Society for Blood and Marrow Transplantation
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Autografting in an AML CR2 Study 1311NTRODUCTION
Despite improvements in the treatment and prog-
osis of acute myeloid leukemia (AML) in recent
ears, disease relapse continues to affect most patients
1,2]. After relapse, a range of treatment options is
vailable, ranging from intensive treatments to pallia-
ive and supportive treatments. The choice of treat-
ent pathway depends on a number of variables,
ncluding the patient’s functional status and age,
eukemia risk group, ability to induce a second re-
ission (CR2), and the availability of allogeneic
onors.
Although CR2 may be achieved in a signiﬁcant pro-
ortion of patients with chemotherapy alone, long-term
urvival is limited (eg, a 3-year survival rate of 8%–18%)
nless transplantation is performed [3]. The availability
f matched sibling donors is limited, and although
atched unrelated donors (MUDs) are available for
ome, the risks of allogeneic transplantation may be
onsidered too great in many patients. Autologous trans-
lantation presents an alternative means of delivering
yeloablative treatment in relapsed AML and has been
ssociated with lower risk of treatment-related mortality
TRM). Although the risk of infusing leukemic cells has
een demonstrated [4], a number of limited case series
ave supported long-term remission after autologous
ransplantation in AML in the salvage setting, with du-
able CR2 in 25%–46% of patients overall in relapsed
ML [5-9] and in  50% of those with acute promy-
locytic leukemia [10,11].
We used the British Society of Blood and Marrow
ransplantation (BSBMT) registry to identify cases of
elapsed AML treated with autologous transplantation
n CR2 between 1982 and 2003. The aim of this study
as to use the data from this large group of patients
ith long-term follow-up to retrospectively analyze
he long-term outcomes of autologous transplantation
s a consolidation treatment for AML in CR2, and to
elate outcome to demographic, disease-related, and
rocedural aspects of treatment.
ETHODS
atient Identification
This was a retrospective, observational study. Pa-
ients age 16 or older with a diagnosis of AML who
ad received an autologous transplantation in CR2
ere identiﬁed from the BSBMT database. Also in-
luded are 6 patients with AML diagnosed when they
ere age  16 years (median age, 15 years; range,
1–15 years). Transplantation units in the United
ingdom are required to report basic transplantation
nd demographic data to the BSBMT. A total of 152
atients were identiﬁed from 28 participating centers.
ll centers were contacted to verify the data already
ontained in the BSBMT database and to collect non- ftandard data, including cytogenetics, harvesting in-
ormation, and details of conditioning regimens. The
tudy was approved by the BSBMT Clinical Trials
ommittee and the National Health Service (NHS)
esearch and Development Department of Shefﬁeld
eaching Hospitals NHS Trust.
atient Characteristics
Detailed patient characteristics are given in Table 1.
total of 152 patients in CR2 of relapsed AML
eceived an autologous transplant between 1982 and
003. The median age at diagnosis was 45.3 years
range, 11.2–67.7 years) and that at transplantation
as 47.4 years (range, 16.1–69.6 years); the sex ratio
as fairly equal (55% male). Length of ﬁrst remission
CR1) ranged from 24 days to 2496 days (6 years, 10
onths), with a median of 500 days. A total of 42
atients had a CR1 duration of  1 year. Median
ollow-up was 84 months (range, 2–200 months).
Cytogenetic data were available for 104 patients
68%) at diagnosis; 44% of these patients had normal
ytogenetics. The available cytogenetic data showed
hat the group comprised 42% good-risk, 57% stan-
ard-risk, and 1% poor-risk patients, based on the risk
roup stratiﬁcation of the Medicine Research Council
MRC) AML trials [12].
ONDITIONING REGIMENS AND SOURCES
F STEM CELLS
Of the 143 patients for whom the conditioning is
nown, 76% had chemotherapy-alone conditioning
nd 24% had total body irradiation (TBI)-based con-
itioning. The 2 most common regimens, accounting
able 1. Patient Characteristics (n  152)
ge at diagnosis, median (range) 45.3 (11.2–67.7)
ex (M), n (%) 84 (55%)
AB class, n (%)
M0 3 (2%)
M1 19 (15%)
M2 29 (22%)
M3 28 (22%)
M4 31 (24%)
M5 14 (11%)
M5a 1 (1%)
M6 4 (3%)
Unknown 23
isk group, n (%)
Good risk 42 (42%)
Standard risk* 56 (57%)
Poor risk 1 (1%)
Unknown risk 53
ength of CR1, median (range) 500 days (24–2496)
ollow-up, median (range) 2559 days (65–6094)
Standard risk  standard risk cytogenetic abnormalities  normal
cytogenetics.or 70% of the procedures, were busulphan and cy-
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A. D. Chantry et al.1312lophosphamide (BuCy) and cyclophosphamide and
BI (Cy TBI). Other regimens included melphalan
nd etoposide. Most patients were supported with
utologous bone marrow (BM) alone (n  108; 71%);
thers were supported with peripheral blood stem
ells (PBSCs) alone (n 27; 18%) or a combination of
M and PBSCs (n  17; 11%) (Table 2).
tudy End Points and Definitions
Analysis of engraftment, early (100 day) and late
10 year) nonrelapse mortality (NRM), relapse risk
RR), progression-free survival (PFS), and overall sur-
ival (OS) were performed. Data was also analyzed
ith respect to FAB class, cytogenetics, risk stratiﬁca-
ion, duration of CR1, conditioning regimen, and
tem cell source. Engraftment was deﬁned as days to
eutrophil recovery  0.5  109/L sustained over 2
ays.
tatistical Analysis
All statistical analyses were performed using R
13]. OS and PFS were calculated by the Kaplan-
eier method, and univariate comparisons were made
sing the log-rank statistic for binary or categorical
omparisons and using Cox’s proportional hazard re-
ression for ordered multiple comparisons (eg, age
roup or year of transplantation) [14]. NRM and RR
ere treated as competing risks and compared using
umulative incidence [15]. P values  .05 were con-
idered signiﬁcant.
able 2. Conditioning Regimens, Sources of Stem Cells, and Timing
f Harvest
ge at transplantation, median (range) 47.4 (16.1–69.6)
onditioning, n (%)
TBI 35 (24%)
CyTBI 28 (20%)
MelTBI 2 (1%)
BuCyTBI 2 (1%)
Unknown 3 (2%)
Chemotherapy alone 108 (76%)
BEM 18 (13%)
BuCy 73 (51%)
Busulphan 2 (1%)
BuMel 1 (1%)
Melphalan 1 (1%)
BEAM 1 (1%)
Unknown chemotherapy 12 (8%)
Unknown 9
ource of stem cells, n (%)
BM 108 (71%)
PBSC 27 (18%)
BM  PBSC 17 (11%)
iming of harvest, n (%)
CR1 74 (60%)
CR2 41 (33%)
Both 9 (7%)p
Unknown 27ESULTS
OS, PFS, RR, and NRM rates are given in
able 3. Both the 5-year and 10-year OS were 32%.
he 5-year PFS was 30%, and the 10-year PFS was
8%. OS declined from time of transplantation to 5
ears and plateaued between 5 and 10 years. OS and
FS survival curves closely correspond (Figure 1). Of
he 152 patients, 7% had died of NRM before day
00; by 10 years, the NRM had risen to 14%. There
ere 3 nonrelapse deaths after 10 years, 1 due to
ransplantation-related multiorgan failure and 2 con-
idered unrelated to transplantation. Most relapses
ccurred within the ﬁrst 2 years. Of those who re-
apsed, the median time to relapse was 185 days. The
ast relapse in the study period occurred 7.7 years after
utologous transplantation. A total of 18 patients re-
ain alive and progression-free beyond that time,
able 3. Response to Transplantation (n  152)
ngraftment, n (%)
Yes 140 (95%)
No 8 (5%)
Unknown 4
ime to engraftment, median (range) 21 (8–115)
BM 27 (8–115)
PBSC or both 15 (9–40)
P value (BM vs PBSC or both) <.0001
urrent status, n
Alive 52
CR2 45
CR>3 5
Relapse 2
Unknown 0
Dead 100
Relapse 78
Transplant-related 21
Unknown 1
urvival after transplantation*
Median (95% confidence interval) 468 days (385-945)
OS at 1 year 59%
PFS at 1 year 50%
OS at 5 years 32%
PFS at 5 years 30%
OS at 10 years 32%
PFS at 10 years 28%
ate deaths (>10 years) 3
Multiorgan failure,transplant-related 1
Liver failure due to sepsis, not
transplant-related 1
Unrelated clinical condition 1
RM†
100 days 7%
1 year 11%
10 years 14%
rogression or RR†
100 days 15%
1 year 38%
10 years 57%
Kaplan-Meier estimates.
Calculated as competing risks by cumulative incidence.roviding a reasonable indication of plateau. Figure 2
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Autografting in an AML CR2 Study 1313hows a cumulative incidence plot of RR and TRM.
urvival data were analyzed for 3 cohorts: 1982–1989,
990–1996, and 1997–2003. Although there was a
ild trend to better survival over time, as would be
xpected with improved transplantation procedures,
he P value of .07 was not signiﬁcant (Figure 3).
ytogenetics and FAB Type
OS at 5 years was 58% for the good-risk group,
9% for the standard-risk group (P .02), and 0% for
he poor-risk group (although only 1 patient included
n this study was designated as poor risk). Figure 4
hows OS by risk group, with good risk separated into
3 and others [inv16/t(8;21)] and compared with stan-
Figure 1. OS and PFS.
igure 2. Cumulative incidence plot of RR and NMR. Three
atients died more than 10 years after transplantation; 1 due to
espiratory failure attributed to TBI-induced lung ﬁbrosis and the[ther 2 unrelated to treatment or relapse.ard risk. OS at 5 years in patients with FAB-type M3
ompared with other good-risk patients, standard-risk
atients, and poor-risk patients was 66%, 42%, 29%,
nd 0%, respectively (P  .008; P refers to a 4-way
omparison).
ength of CR1
To establish the duration of CR1 that resulted in
he greatest difference in survival, patients were di-
hotomized into groups with CR1 greater or less than
eﬁned posttransplantation periods, and the highest
egree of statistical signiﬁcance was established. Pa-
ients with CR1 of  8 months had the most signiﬁ-
antly improved OS (1-year OS of 66% vs 31%; P 
0001). There were no long-term survivors in the
roup with CR1  8 months, but for patients with
Figure 3. OS by year of transplantation.
igure 4.OS by risk group; good risk separated into M3 and others
inv16/t(8;21)] compared with standard risk.
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A. D. Chantry et al.1314R1  8 months, OS at 5 and 10 years was 37%
Figure 5). Dichotomizing the patients into those with
R1 of  12 months and  12 months also yielded
igniﬁcant results, with 5-year OS of 23% versus 10-
ear OS of 38% (P  .02).
atient Age
OS was signiﬁcantly better in younger patients.
onsidering age at diagnosis, OS was 52% in patients
ge  30 years, 35% in those age 30–49 years, and
7% in those age  50 years (P  .005). Similarly,
onsidering age at transplantation, OS was 45% in
atients age  30 years, 37% in those age 30–49
ears, and 22% in those age  50 years (P  .026)
Figure 6).
Figure 5. OS by duration of CR1.sFigure 6. OS by age at transplantation.onditioning Regimen
No signiﬁcant difference in OS at 5 years was
ound between patients treated with TBI-based or
hemotherapy-only conditioning regimens: 32% ver-
us 33% (P  .7). Late nonrelapse deaths occurred in
oth groups.
ime of Harvest
OS was improved when the stem cell harvest used
as obtained entirely within the CR1 compared with
arvest obtained during CR2 (38% vs 23%; P  .025)
Figure 7). PFS also was signiﬁcantly improved with
ntire CR1 harvest compared with CR2 harvest (35%
s 22%; P  .009). There were no signiﬁcant differ-
nces in RR and TRM between the 2 groups.
ource of Stem Cells
Neutrophil engraftment of 0.5  109/L for at
east 2 consecutive days was achieved in most patients
here recorded (94%). The median time to engraft-
ent was 21 days (range, 8–115 days). As expected,
edian time to engraftment using PBSC  BM was
uicker at 15 days, compared with 27 days using BM
lone (P .0001). There were no signiﬁcant differences
n OS, PFS, RR, and NRM based on the source of
utologous rescue comparing BM alone and PBSC
M (P  .64). Data relating to platelet engraftment
ime were not available.
ultivariate Analysis
Multivariate analysis was performed using Cox’s
roportional hazard regression. Considering OS,
ength of CR1 remission 8 months (P .00012) and
RC risk group stratiﬁcation (P  .01) were identi-
ed as signiﬁcant independent variables. For PFS, the
Figure 7. OS by timing of harvest.ame 2 variables—length of CR1  8 months (P 
.
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Autografting in an AML CR2 Study 13150001) and MRC risk group (P  .004)—were identi-
ed as signiﬁcant.
ISCUSSION
This retrospective study summarizes a national
xperience of autologous transplantation as a consol-
dation treatment in adult patients with AML who
ave relapsed but have achieved CR2. As with any
etrospective study, it may be susceptible to selection
ias. For example, the criteria for patient selection are
ot predeﬁned, and clinicians may have selected only
tter patients from standard-risk and good-risk cyto-
enetic prognostic groups for the procedure. Indeed,
ecause 50% of patients achieve CR2 [3], the fact that
hese patients had achieved CR2 introduces a favorable
egree of bias, and the results of this study should not be
aken as outcomes of salvage of relapsed AML overall.
Nevertheless, this is one of the largest series con-
idered to date. It has a long follow-up period and
rovides a reference for outcome data in the United
ingdom. Although there were trends showing im-
roved OS, PFS, and NRM over time (presumably
elated to better supportive care and greater experi-
nce), these were not statistically signiﬁcant. These
bservations, and the fact that the practice of autolo-
ous transplantation in AML has changed relatively
ittle over time, indicate that it is reasonable to draw
onclusions for application to current clinical practice
n long-term data from the last 2 decades.
The 5-year OS of 32% demonstrates that autolo-
ous transplantation is a valid therapeutic option for
dults with relapsed, standard-risk, and good-risk
ML who achieve CR2 and conﬁrms the results of
imilar retrospective studies with disease-free proba-
ilities of 30%–35% [7,8]. In our study, the results
pply to a broad age range of patients (age 16–69
ears) and were achieved with a relatively low NRM
7% at 100 days and 14% at 10 years). This compares
avorably with rates reported in other studies, which
ange from 4% to 27% [5,6,16].
This study conﬁrms that outcome for autologous
ransplantation in acute promyelocytic leukemia is
articularly good, with approximately 2/3 of patients
chieving prolonged survival. This compares favor-
bly with outcomes from therapy with speciﬁc agents,
uch as ATRA and arsenic trioxide [10,11]. Given the
oxicity associated with allogeneic transplantation, au-
ologous transplantation may be the best treatment
ption for patients with acute promyelocytic leukemia
n CR2. Our ﬁndings also conﬁrm the improved out-
ome in younger patients and those with CR1  8
onths in whom adequate autologous harvests were
ollected during CR1.
The ﬁndings of this study provide information to
elp optimize the use of autologous transplantation. rlearly, patients with M3 beneﬁt the most, although
oderately successful outcomes were achieved in
hose with standard-risk disease. Autologous trans-
lantation is best restricted to patients with CR1  8
onths. Interestingly, although TBI has been consid-
red advantageous in treating AML, the survival
urves for treatment with and without TBI were al-
ost identical. The choice of myeloablative treatment
ay be best based on which treatment will likely
inimize toxicity. Moreover, in many units, chemo-
herapy-only conditioning will be advantageous be-
ause of the limited and restricted scheduling of TBI.
In relation to the choice of autologous rescue, our
ndings suggest that outcomes are best if the harvest
sed is obtained entirely during CR1, with collections
f PBSCs forming at least part of the graft. Why
utcomes are superior with harvests obtained during
R1 is unclear, but it may be related to less contam-
nation or perhaps to more chemosensitive disease,
ess dysplasia, or other biological factors associated
ith the leukemia. Nevertheless, although collection
f a full PBSC harvest during CR1 may be difﬁcult,
he suggestion of superior outcomes in this study may
ustify a more systematic and aggressive approach to
arvesting during CR1, with a combination of multiple
BSCs combined with BM harvesting when necessary.
lthough relatively few patients in this study received
BSCs (27%), autologous rescue now routinely contains
PBSC component, suggesting that a prospective anal-
sis will demonstrate further improvements in outcome.
Despite the results of this study of autologous
ransplantation, HLA-matched sibling allogeneic
ransplantation with myeloablative conditioning is
ikely to remain the treatment of choice for relapsed
ML in CR2 when available [17]. However, its appli-
ability is restricted by donor availability and also by
he age and ﬁtness of patients. Recently reported re-
ults from the UK MRC comparing HLA-matched
ibling allogeneic transplantation, MUD transplanta-
ion, and autologous transplantation in AML CR2
eported 5-year OS of 54%, 40%, and 33%, respec-
ively [18]. These ﬁgures provide a useful comparison
o the data of the present study but may not be entirely
omparable, because of the tendency for MUD trans-
lantation to be limited on grounds of tolerability to
ounger patients, in whom outcomes with autologous
ransplantation are better than average (eg, patients
ge  30 years had a 5-year OS of 45% with autolo-
ous transplantation). Moreover, MUD transplanta-
ion is complicated by higher rates of graft-versus-
ost disease, increased susceptibility to infection,
educed quality of life, and increased risk of late death,
specially in older patients. The ﬁnancial costs are also
onsiderably higher for MUD transplantation com-
ared with autologous transplantation.
Recently reported results of an international ret-
ospective analysis of autologous transplantation ver-
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A. D. Chantry et al.1316us MUD transplantation for AML in CR1 and CR2
eveal adjusted 3-year survival probabilities of 57%
53%–61%) after autologous transplantation com-
ared with 44% (37%–51%) after MUD transplanta-
ion in CR1 and 46% (39%–53%) after autologous
ransplantation and 33% (28%–38%) after MUD
ransplantation in CR2 [9]. The authors of that study
oted that although relapse was less frequent with
UD transplantation, the high TRM offset the supe-
ior antileukemia effect of MUD transplantation.
Reduced-intensity transplantation is another ther-
peutic option for treating relapsed AML that offers a
otentially curative graft-versus-leukemia effect and
onsiderably lower NRM, thus expanding the number
f potential recipients [19]. OS rates of 30%–50%
ave been reported [20-25]. Therefore, a prospective
rial comparing autologous transplantation with
UD transplantation and/or reduced-intensity trans-
lantation may be reasonable and would provide the
pportunity to address practical issues unresolved by
his and other analyses, including decisions related to
atient age and economic issues. The design and se-
ection criteria of a prospective trial would require
areful consideration. Elderly patients and those with
oor-risk cytogenetics are unlikely to beneﬁt from
utologous transplantation. However, for younger pa-
ients and those with standard-risk or good-risk cyto-
enetics, the superior treatment option is not yet
learly established. A prospective trial with 3 arms
omparing autologous transplantation, MUD trans-
lantation, and reduced-intensity transplantation
ould address this issue.
Outcomes of autologous transplantation also may
e improved if this therapy were combined with cur-
ent developmental approaches. Given the possibility
hat reinfused cells are the source of relapse [4], pre-
ious studies have investigated purging techniques.
any of these studies have used relatively crude tech-
iques (eg, ex vivo chemotherapy) for purifying the
utologous graft [7,26] and have failed to show a
eneﬁt. More sophisticated biotechnology now exists,
hich may result in more effective decontamination
ithout compromising graft function [27].
It may be reasonable to consider myeloablation
nd autologous transplantation as a relatively safe but
rofound debulking treatment, after which minimal
esidual disease could be eliminated using pharmaco-
ogic or immunologic “maintenance” therapies. Many
ovel agents for treating AML are currently under
nvestigation, some of which may be more effective as
aintenance therapies directed at minimal residual
isease posttransplantation. Reduced-intensity trans-
lantation may be more effective if used as cellular
mmunotherapy against MRD after autologous trans-
lantation. Combined autologous and reduced-inten-
ity allogeneic transplantation has been shown to be
easible for treating various diseases [28].In conclusion, autologous transplantation should
emain a routine option in the treatment of patients
ith relapsed AML, particularly those with M3 and
hose with standard-risk disease when there no HLA-
atched sibling donor is available. Consideration
hould be given to harvesting during CR1 in patients
acking an allogeneic donor. Avenues may be available
o improve outcome by incorporating new biotechno-
ogical, pharmacologic, and cellular immunotherapy
pproaches. Prospective comparison with MUD
ransplantation and reduced-intensity transplantation
ould provide further evidence on which to base the
hoice of treatment.
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